dabigatran has been researched along with dalteparin in 86 studies
| Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) | Studies (dalteparin) | Trials (dalteparin) | Recent Studies (post-2010) (dalteparin) |
|---|---|---|---|---|---|
| 3,887 | 261 | 3,490 | 5,665 | 1,423 | 2,267 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (19.77) | 29.6817 |
| 2010's | 61 (70.93) | 24.3611 |
| 2020's | 8 (9.30) | 2.80 |
| Authors | Studies |
|---|---|
| Ahnfelt, L; Bravo, ML; Büller, HR; Dahl, OE; Eriksson, BI; Hettiarachchi, R; Kälebo, P; Piovella, F; Reilly, P; Rosencher, N; Stangier, J | 1 |
| Ma, Q | 1 |
| Büller, HR; Christiansen, AV; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kälebo, P; Kurth, AA; Rosencher, N; Schnee, J; van Dijk, CN | 1 |
| Norrie, J | 1 |
| Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN | 1 |
| Martins, HS; Scalabrini-Neto, A; Velasco, IT | 1 |
| Caprini, JA; Clements, ML; Comp, PC; Davidson, BL; Francis, CW; Friedman, RJ; Ginsberg, JS; Hantel, S; Huo, MH; Lieberman, JR; Muntz, JE; Raskob, GE; Schnee, JM | 1 |
| Francis, CW | 1 |
| Eikelboom, JE; Weitz, JI | 1 |
| Caprini, JA; Eriksson, BI; Plumb, JM; Roskell, NS; Wolowacz, SE | 1 |
| Beard, SM; Brenkel, IJ; Dolan, G; Maciver, F; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE | 1 |
| Harenberg, J; Nitschmann, S | 1 |
| Barry, M; McCullagh, L; Tilson, L; Walsh, C | 1 |
| Carroll, C; Holmes, M; Papaioannou, D | 1 |
| Brenkel, IJ; Clemens, A; Dolan, G; Noack, H; Plumb, JM; Robinson, PA; Roskell, NS; Wolowacz, SE | 1 |
| Verma, AK | 1 |
| Kolundzic, R; Trkulja, V | 1 |
| Caprini, JA; Clemens, A; Dahl, OE; Eriksson, BI; Francis, CW; Friedman, RJ; Hantel, S; Kurth, AA; Rosencher, N; Schnee, JM | 1 |
| Brant, R; Hull, RD; Liang, J | 1 |
| Margieva, AV; Omel'ianovskiĭ, VV; Tsfasman, FM; Zagorodniĭ, NV | 1 |
| Clemens, A; Monz, BU; Plumb, JM | 1 |
| Dahl, OE; Huisman, MV; Quinlan, DJ; Schulman, S | 1 |
| Kwok, CS; Loke, YK | 1 |
| Dahl, OE; Eriksson, BI; Friedman, RJ; Hantel, S; Hermansson, K; Huo, MH; Kurth, AA; Schnee, JM | 1 |
| Ageno, W; Prandoni, P | 1 |
| Diamantopoulos, A; Lees, M; Lereun, C; Rasul, F; Sengupta, N; Wells, P | 1 |
| Abel, S; Camp, CL; Ereth, MH; McKellar, SH; Schaff, HV; Suri, RM | 1 |
| Matziolis, D; Matziolis, G; Perka, C | 1 |
| Fadda, V; Maratea, D; Messori, A; Trippoli, S | 1 |
| Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R | 1 |
| Friedman, RJ | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Kurth, AA; Noack, H; Rosencher, N | 1 |
| Clemens, A; Feuring, M; Härtter, S; Sennewald, R; Stangier, J; van Ryn, J; Yamamura, N | 1 |
| Migliaccio-Walle, K; Rublee, D; Simon, TA | 1 |
| Espada, NG; González, TC; Merino, RG; Nieto, JA | 1 |
| Finsterer, J; Reiter, M; Schäffl-Doweik, L; Stöllberger, C | 1 |
| Barry, M; McCullagh, L; Walsh, C | 1 |
| Gómez-Outes, A; Suárez-Gea, ML; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Clemens, A; Dahl, OE; Eriksson, BI; Hantel, S; Kurth, AA; Rosencher, N | 1 |
| Dahl, OE; Harenberg, J; Marder, VJ; Marx, S; Schulze, A; Wehling, M; Weiss, C | 1 |
| Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C | 1 |
| Kwok, CS; Loke, YK; Pradhan, S; Yeong, JK | 1 |
| Klein, HH | 1 |
| Cohen, AA; Rider, T | 1 |
| Brosa, M; Diamantopoulos, A; Folkerts, K; Imberti, D; Monreal, M | 1 |
| Dugdale, M; Fabian, TC; Gordon, JL; Lee, MD | 1 |
| Clemens, A; Fraessdorf, M; Friedman, J | 1 |
| Gálity, H; Gombár, C; Horvath, G; Sisák, K; Tóth, K | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Avendaño-Solá, C; Gómez-Outes, A; Terleira-Fernández, AI; Vargas-Castrillón, E | 1 |
| Feuerstein, JD; Ketwaroo, GA; Leffler, DA; Patwardhan, VR; Sengupta, N; Tapper, EB; Thaker, AM | 1 |
| Cattaneo, M; Lussana, F; Squizzato, A | 1 |
| Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Ardillon, L; Boon, LM; Eeckhoudt, S; Hermans, C; Lambert, C | 1 |
| Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J | 1 |
| Rostagno, C | 1 |
| Ansell, JE | 1 |
| Francart, S; Francis, CW; Gosselin, RC; Gudmundsdottir, BR; Hawes, E; Letertre, LR; Malmstrom, RE; Moll, S; Onundarson, PT; Skeppholm, M | 1 |
| Crijns, HJ; De Boer, HC; De Jong, AM; Kamphuisen, PW; Kuiper, M; Lau, DH; Linz, D; Lumeij, S; Maass, AH; Rienstra, M; Schotten, U; Spronk, HM; Ten Cate, H; Van Gelder, IC; van Hunnik, A; van Zonneveld, AJ; Verheule, S; Zeemering, S | 1 |
| Babhulkar, S; Clemens, A; Dadi, A; Iyer, R; Kamath, S; Malhotra, R; Mody, B; Mutha, S; Reddy, G; Sanjib, KB; Shah, V; Shetty, N; Tapasvi, S; Wadhwa, M | 1 |
| Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG | 1 |
| Chaiyakunapruk, N; Chongmelaxme, B; Kotirum, S | 1 |
| Gage, BF; Ganti, BR; Lee, ED; Lin, H; Nunley, RM; Venker, BT | 1 |
| Adelmeijer, J; Bos, S; Boyett, SL; Daita, K; Lisman, T; Potze, W; Sanyal, AJ; Siddiqui, MS | 1 |
| An, SJ; Kim, CK; Kim, TJ; Ko, SB; Nam, KW; Oh, K; Yoon, BW | 1 |
| Chu, XC; Gao, JH; Ning, B; Wang, LL; Zhao, CX | 1 |
| Ahuja, T; Cirrone, F; Green, D; Papadopoulos, J; Raco, V; Xiang, E | 1 |
| Gheysens, O; Goffin, KE; Hoylaerts, MF; Jacquemin, M; Liesenborghs, L; Peerlinck, K; Peetermans, M; Peetermans, WE; Vanassche, T; Verhaegen, J; Verhamme, P; Wijngaerden, EV | 1 |
| Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M | 1 |
| Azboy, I; Groff, H; Parvizi, J | 1 |
| Carrier, M; Khorana, AA; Lee, AYY; Meyer, G; Noble, S; O'Connell, C; Soff, G | 1 |
| Bawa, H; Dirschl, DR; Luu, HH; Weick, JW | 1 |
| Batistatou, A; Gkiatas, I; Korompilias, AV; Kostas, I; Papadopoulos, D; Papoudou-Bai, A; Tsantes, AG | 1 |
| Aydin Ozturk, P; Ozturk, U; Yilmaz, T | 1 |
| Nowak, K; Pac, A; Stepien, K; Undas, A; Zalewski, J | 1 |
| Arantes, FBB; Baracioli, LM; Barbosa, CJDG; Dalçoquio, TF; Franci, A; Furtado, RHM; Kalil Filho, R; Menezes, FR; Nakashima, CAK; Nicolau, JC; Nomelini, QSS; Ramires, JAF | 1 |
| Adademir, T; Aksoy, R; Baş, T; Başaran, EK; Çevirme, D; Elibol, A; Keser, S; Savluk, ÖF; Yılmaz, B | 1 |
| Choi, S; Hwang, KT; Jeong, SY; Koo, JW; Lee, JK; Park, KC | 1 |
| Hofmann, ER; Isaacs, DJ; Johnson, EJ; Rangarajan, S; Vinson, DR | 1 |
| Brouwer, RW; Gerritsma-Bleeker, CL; Segers, M; van der Veen, L; van Hulst, M; van Raay, JJ; Veeger, NJ | 1 |
| Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH | 1 |
| Gromov, K; Jensen, TB; Jimenez-Solem, E; Olesen, JB; Overgaard, S; Petersen, J; Schelde, AB | 1 |
| Brito, NC; de Brito, AFS; Ferreira Júnior, ABS; Ferreira, VL; Nita, ME; Riveros, BS; Tanaka, SKT | 1 |
24 review(s) available for dabigatran and dalteparin
| Article | Year |
|---|---|
Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism | 2009 |
Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Dabigatran; Elective Surgical Procedures; Enoxaparin; Fondaparinux; Humans; Polysaccharides; Pyridines; Quality-Adjusted Life Years; Venous Thromboembolism | 2009 |
Rivaroxaban vs dabigatran for thromboprophylaxis after joint-replacement surgery: exploratory indirect comparison based on meta-analysis of pivotal clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Postoperative Care; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Safety; Survival Analysis; Thiophenes; Venous Thromboembolism | 2010 |
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Chi-Square Distribution; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Female; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2010 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pulmonary Embolism; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis | 2011 |
Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Enoxaparin; Humans; Pyridines; Venous Thromboembolism; Warfarin | 2011 |
Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2011 |
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected].
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Dabigatran; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency; Venous Thromboembolism | 2012 |
Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Endpoint Determination; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2012 |
Relative effects of two different enoxaparin regimens as comparators against newer oral anticoagulants: meta-analysis and adjusted indirect comparison.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Morpholines; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2013 |
[Electrical cardioversion for non-valvular atrial fibrillation--underestimated risk for thromboembolic complications?].
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Electric Countershock; Enoxaparin; Heparin; Humans; International Normalized Ratio; Morpholines; Phenprocoumon; Practice Guidelines as Topic; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Warfarin | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Enoxaparin; Humans; Morpholines; Postoperative Hemorrhage; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulant and antiplatelet medications encountered in emergency surgery patients: a review of reversal strategies.
Topics: Anticoagulants; Aspirin; Benzimidazoles; Clopidogrel; Dabigatran; Emergencies; Enoxaparin; Fondaparinux; Heparin; Humans; Morpholines; Platelet Aggregation Inhibitors; Platelet Transfusion; Polysaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Surgical Procedures, Operative; Thiophenes; Ticlopidine; Warfarin | 2013 |
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment.
Topics: Acute Coronary Syndrome; Antithrombins; Atrial Fibrillation; Benzimidazoles; Chi-Square Distribution; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Humans; Myocardial Infarction; Odds Ratio; Pyridines; Risk Assessment; Risk Factors; Stroke; Treatment Outcome; Venous Thromboembolism; Warfarin | 2013 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Post-operative arterial thrombosis with non-vitamin K antagonist oral anticoagulants after total hip or knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brain Ischemia; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Postoperative Complications; Postoperative Hemorrhage; Prothrombin; Pulmonary Embolism; Pyrazoles; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Treatment Outcome | 2015 |
New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.
Topics: Administration, Oral; Anticoagulants; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; Polysaccharides; Rivaroxaban; Venous Thromboembolism | 2016 |
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Arginine; Blood Coagulation Disorders; Blood Coagulation Factors; Coagulants; Combined Modality Therapy; Dabigatran; Drugs, Investigational; Enoxaparin; Factor Xa; Fibrinolytic Agents; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins; Vitamin K | 2016 |
Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2017 |
Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis.
Topics: Anticoagulants; Arthroplasty; Azetidines; Benzylamines; Dabigatran; Enoxaparin; Heparin; Heparin, Low-Molecular-Weight; Humans; Network Meta-Analysis; Postoperative Complications; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Treatment Outcome; Venous Thromboembolism; Warfarin | 2017 |
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin | 2021 |
Thromboprophylaxis of Patients Submitted to Total Hip and Knee Arthroplasty: A Cost-Effectiveness Assessment From the Perspective of the Brazilian National Health System.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Brazil; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolism | 2022 |
15 trial(s) available for dabigatran and dalteparin
| Article | Year |
|---|---|
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Female; Humans; Male; Middle Aged; Odds Ratio; Postoperative Complications; Postoperative Period; Pyridines; Regression Analysis; Thrombin; Thromboembolism | 2005 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Enzyme Tests; Dabigatran; Double-Blind Method; Drug Administration Routes; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Postoperative Complications; Prodrugs; Pyridines; Treatment Outcome; Venous Thrombosis | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Pyridines; Thromboembolism; Venous Thrombosis | 2007 |
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Dose-Response Relationship, Drug; Double-Blind Method; Enoxaparin; Europe; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; North America; Outcome Assessment, Health Care; Pyridines; Risk Factors; Thrombin; Venous Thromboembolism | 2009 |
Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Follow-Up Studies; Hemorrhage; Humans; Morpholines; Postoperative Complications; Prospective Studies; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism; Withholding Treatment | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Survival Analysis; Venous Thromboembolism; Venous Thrombosis | 2011 |
Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.
Topics: Adult; Anticoagulants; Antithrombins; Benzimidazoles; Biological Availability; Blood Coagulation; Cross-Over Studies; Dabigatran; Drug Interactions; Drug Monitoring; Enoxaparin; Feasibility Studies; Female; Half-Life; Humans; Male; Middle Aged; Pyridines | 2012 |
Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2012 |
Efficacy of delayed thromboprophylaxis with dabigatran: pooled analysis.
Topics: Aged; Anticoagulants; Antithrombins; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; Middle Aged; Orthopedic Procedures; Prospective Studies; Pyridines; Treatment Outcome; Venous Thromboembolism | 2012 |
Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost of Illness; Cost-Benefit Analysis; Dabigatran; Direct Service Costs; Enoxaparin; France; Humans; Italy; Models, Theoretical; Morpholines; Postoperative Complications; Pyridines; Quality of Life; Rivaroxaban; Spain; Thiophenes; Venous Thromboembolism | 2013 |
Comparison of minor bleeding complications using dabigatran or enoxaparin after cemented total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Humans; Male; Middle Aged; Postoperative Hemorrhage; Prospective Studies | 2014 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Postoperative Complications; Prospective Studies; Rivaroxaban; Ultrasonography, Doppler; Venous Thrombosis | 2015 |
Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
Topics: Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Confidence Intervals; Dabigatran; Double-Blind Method; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; India; Injections, Subcutaneous; Male; Middle Aged; Odds Ratio; Postoperative Complications; Primary Prevention; Prospective Studies; Risk Assessment; Treatment Outcome; Venous Thromboembolism | 2017 |
Targeting Coagulase Activity in Staphylococcus aureus Bacteraemia: A Randomized Controlled Single-Centre Trial of Staphylothrombin Inhibition.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Bacteremia; Belgium; Blood Coagulation; Coagulase; Dabigatran; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Pilot Projects; Pipecolic Acids; Prospective Studies; Staphylococcal Infections; Staphylococcus aureus; Sulfonamides; Thrombin; Thrombosis; Time Factors; Treatment Outcome | 2018 |
Bleeding complications of thromboprophylaxis with dabigatran, nadroparin or rivaroxaban for 6 weeks after total knee arthroplasty surgery: a randomised pilot study.
Topics: Activities of Daily Living; Anticoagulants; Arthroplasty, Replacement, Knee; Dabigatran; Female; Humans; Nadroparin; Netherlands; Pilot Projects; Postoperative Care; Postoperative Complications; Quality of Life; Rivaroxaban; Treatment Outcome; Venous Thromboembolism | 2021 |
47 other study(ies) available for dabigatran and dalteparin
| Article | Year |
|---|---|
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Drug Delivery Systems; Drug Design; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Postoperative Hemorrhage; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism; Venous Thrombosis; Warfarin | 2007 |
Trials of venous thromboembolism prevention.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Postoperative Complications; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Venous Thrombosis | 2007 |
Dabigatran versus enoxaparin after total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Humans; Phlebography; Postoperative Complications; Pyridines; Venous Thromboembolism | 2007 |
New issues in oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Clinical Trials as Topic; Cytochrome P-450 CYP2C9; Dabigatran; Enoxaparin; Genetic Variation; Humans; Mixed Function Oxygenases; Morpholines; Pharmacogenetics; Polymorphism, Genetic; Pyridines; Rivaroxaban; Thiophenes; Vitamin K Epoxide Reductases; Warfarin | 2008 |
Dabigatran etexilate for prevention of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Dabigatran; Enoxaparin; Hemorrhage; Humans; Pyridines; Risk Assessment; Treatment Outcome; Venous Thromboembolism | 2009 |
[Thrombin inhibitor shows stable safety profile in the practice].
Topics: Administration, Oral; Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Middle Aged; Primary Prevention; Prodrugs; Pyridines; Thrombin; Venous Thromboembolism | 2008 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Enoxaparin; Female; Hemorrhage; Humans; Longitudinal Studies; Male; Markov Chains; National Health Programs; Pyridines; United Kingdom; Venous Thromboembolism | 2009 |
[New agents for the prevention of venous thromboembolism].
Topics: Benzimidazoles; Dabigatran; Enoxaparin; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Drug Approval; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; France; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Prodrugs; Pyridines; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Vitamin K | 2009 |
A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Fibrinolytic Agents; Humans; Ireland; Models, Economic; Monte Carlo Method; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism in patients aged over 75 years or with moderate renal impairment undergoing total knee or hip replacement.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Health Care Costs; Hemorrhage; Humans; Kidney Diseases; Postoperative Complications; Pyridines; United Kingdom; Venous Thromboembolism | 2010 |
New agents for orthopaedic thromboprophylaxis: caution essential, but time will tell.
Topics: Anticoagulants; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Morpholines; Orthopedic Procedures; Postoperative Complications; Pyridines; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2009 |
Pooled analysis of trials may, in the presence of heterogeneity inadvertently lead to fragile conclusions due to the importance of clinically relevant variables being either hidden or lost when the findings are pooled.
Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dabigatran; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; Evidence-Based Medicine; Fibrinolytic Agents; Hemorrhage; Humans; Injections, Subcutaneous; Meta-Analysis as Topic; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Assessment; Risk Factors; Treatment Outcome; Venous Thromboembolism | 2010 |
[Cost-effectiveness analysis of methods for thromboprophylaxis after orthopedic surgery].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Postoperative Complications; Pyridines; Thromboembolism; Treatment Outcome | 2010 |
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Dabigatran; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Models, Economic; Morpholines; Polysaccharides; Postoperative Complications; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Thiophenes; Treatment Outcome; Venous Thromboembolism | 2010 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Humans; Postoperative Complications; Randomized Controlled Trials as Topic; Venous Thromboembolism; Venous Thrombosis | 2011 |
An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Female; Health Care Costs; Humans; Male; Middle Aged; Morpholines; Postoperative Complications; Risk; Risk Factors; Rivaroxaban; Thiophenes; Venous Thromboembolism | 2011 |
Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombins; Aortic Valve; Benzimidazoles; Blood Coagulation; Blood Platelets; Dabigatran; Enoxaparin; Fibrinolytic Agents; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Injections, Subcutaneous; Prosthesis Design; Pyridines; Swine; Thrombelastography; Thrombosis; Time Factors | 2011 |
Thromboembolism prophylaxis with dabigatran leads to lower perioperative blood loss than with dalteparin in primary knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin Proteins; Arthroplasty, Replacement, Knee; Benzimidazoles; Blood Loss, Surgical; Case-Control Studies; Dabigatran; Dalteparin; Female; Humans; Male; Middle Aged; Pyridines; Retrospective Studies; Thromboembolism | 2011 |
Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Cost-Benefit Analysis; Dabigatran; Decision Trees; Drug Costs; Elective Surgical Procedures; Enoxaparin; Female; Humans; Male; Markov Chains; Models, Economic; Morpholines; Postoperative Complications; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; State Medicine; Thiophenes; United Kingdom; Venous Thromboembolism | 2012 |
Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy.
Topics: Aged; Anticoagulants; Antithrombins; Arterial Occlusive Diseases; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cerebral Angiography; Dabigatran; Drug Monitoring; Drug Therapy, Combination; Embolectomy; Embolism; Enoxaparin; Fatal Outcome; Femoral Artery; Humans; International Normalized Ratio; Male; Phenprocoumon; Vertebrobasilar Insufficiency | 2012 |
Value-of-information analysis to reduce decision uncertainty associated with the choice of thromboprophylaxis after total hip replacement in the Irish healthcare setting.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Cost-Benefit Analysis; Dabigatran; Decision Making; Enoxaparin; Guidelines as Topic; Health Care Costs; Humans; Ireland; Models, Economic; Morpholines; Pyridines; Quality-Adjusted Life Years; Rivaroxaban; Technology Assessment, Biomedical; Thiophenes; Time Factors; Venous Thromboembolism | 2012 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Budgets; Cost Control; Dabigatran; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Morpholines; Polysaccharides; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Spain; State Medicine; Thiophenes; Venous Thromboembolism | 2012 |
Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Economics, Pharmaceutical; Enoxaparin; Models, Economic; Pyrazoles; Pyridones; Rivaroxaban; Spain; Treatment Outcome; Venous Thromboembolism | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Heparin; Humans; Ischemic Attack, Transient; Longitudinal Studies; Male; Middle Aged; Morpholines; Patient Readmission; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiophenes; Thromboembolism; Venous Thrombosis; Warfarin; Withholding Treatment | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Dabigatran etexilate versus low-molecular weight heparin to control consumptive coagulopathy secondary to diffuse venous vascular malformations.
Topics: Adult; Anticoagulants; Blood Platelets; Dabigatran; Disseminated Intravascular Coagulation; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Humans; Platelet Count; Thrombosis; Vascular Malformations | 2016 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Progression; Embolization, Therapeutic; Female; Femoral Vein; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Lung; Mice; Mice, Inbred C57BL; Microscopy, Video; Pulmonary Embolism; Thrombosis; Venous Thromboembolism; Venous Thrombosis | 2016 |
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Donors; Calibration; Dabigatran; Enoxaparin; Factor X; Female; Fondaparinux; Heparin; Humans; International Normalized Ratio; Male; Polysaccharides; Prothrombin; Prothrombin Time; Pyrazoles; Pyridones; Reproducibility of Results; Rivaroxaban; Thromboplastin; Warfarin | 2016 |
Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation.
Topics: Analysis of Variance; Animals; Antithrombins; Atrial Fibrillation; Cell Proliferation; Dabigatran; Female; Fibrinolytic Agents; Fibroblasts; Fibrosis; Goats; Heart Atria; Indazoles; Mice, Transgenic; Nadroparin; Peptide Hydrolases; Pyrroles; Quinazolines; Rats; Receptors, Thrombin; Thrombin; Thrombophilia; Urea | 2017 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation; Dabigatran; Enoxaparin; Female; Humans; Lower Extremity; Male; Middle Aged; Osteoarthritis, Hip; Perioperative Care; Postoperative Complications; Retrospective Studies; Risk Adjustment; Russia; Thrombosis | 2016 |
A cost-utility analysis of dabigatran, enoxaparin, and usual care for venous thromboprophylaxis after hip or knee replacement surgery in Thailand.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit Analysis; Dabigatran; Decision Trees; Enoxaparin; Health Care Costs; Humans; Monte Carlo Method; Postoperative Complications; Premedication; Quality-Adjusted Life Years; Thailand; Venous Thromboembolism | 2017 |
Changes of in vitro potency of anticoagulant drugs are similar between patients with cirrhosis due to alcohol or non-alcoholic fatty liver disease.
Topics: Adult; Alcoholism; Anticoagulants; Dabigatran; Enoxaparin; Female; Hemostasis; Humans; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrazoles; Pyridones; Thrombosis | 2017 |
Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Dabigatran; Dalteparin; Disability Evaluation; Enoxaparin; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Recurrence; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Seoul; Stroke; Time Factors; Treatment Outcome | 2017 |
Anticoagulation prescribing patterns in patients with cancer.
Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Hemorrhage; Humans; Middle Aged; Neoplasms; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Thrombosis; Treatment Outcome; Venous Thromboembolism; Warfarin | 2018 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dabigatran; Enoxaparin; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Patient Discharge; Pulmonary Embolism; Quebec; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Venous Thromboembolism; Venous Thrombosis | 2018 |
Differences in Reported Outcomes in Industry-Funded vs Nonfunded Studies Assessing Thromboprophylaxis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Conflict of Interest; Dabigatran; Enoxaparin; Female; Fondaparinux; Health Care Sector; Hemorrhage; Humans; Male; Pulmonary Embolism; Pyrazoles; Pyridones; Rivaroxaban; Venous Thromboembolism; Warfarin | 2018 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; Hemorrhage; Humans; Multicenter Studies as Topic; Neoplasms; Observational Studies as Topic; Patient Acceptance of Health Care; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Recurrence; Rivaroxaban; Thiazoles; Venous Thromboembolism; Venous Thrombosis | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Decision-Making; Dabigatran; Databases, Factual; Enoxaparin; Female; Fondaparinux; Humans; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Rivaroxaban; Venous Thrombosis; Warfarin | 2018 |
Antithrombotic efficacy of direct oral anticoagulants on patency rate following microsurgical anastomosis in crushed rat arteries.
Topics: Anastomosis, Surgical; Animals; Dabigatran; Enoxaparin; Factor Xa Inhibitors; Femoral Artery; Male; Microsurgery; Rats; Rats, Wistar; Rivaroxaban; Vascular Patency | 2019 |
Effects of Bemiparin Sodium Versus Dabigatran Etexilate After Anastomosis in Rat Carotid Arteries on the Development of Neointima and Thrombolytic Efficacy.
Topics: Animals; Anticoagulants; Antithrombins; Carotid Arteries; Cerebral Revascularization; Dabigatran; Heparin, Low-Molecular-Weight; Neointima; Rats; Rats, Sprague-Dawley; Thrombosis | 2019 |
Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Comparative Effectiveness Research; Dabigatran; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasms; Pilot Projects; Prospective Studies; Pyrazoles; Pyridones; Recurrence; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome; Venous Thromboembolism; Vitamin K | 2019 |
Influence of Direct Thrombin Inhibitor and Low Molecular Weight Heparin on Platelet Function in Patients with Coronary Artery Disease: A Prospective Interventional Trial.
Topics: Aged; Antithrombins; Coronary Artery Disease; Dabigatran; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies | 2020 |
Effects of anticoagulant drugs on wound healing process in a rat model: a comparative study.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Anticoagulants; Dabigatran; Enoxaparin; Female; Models, Animal; Random Allocation; Rats; Rats, Sprague-Dawley; Rivaroxaban; Saline Solution; Single-Blind Method; Skin; Treatment Outcome; Wound Healing; Wounds and Injuries | 2020 |
Perioperative symptomatic venous thromboembolism after immediate chemoprophylaxis in patients with pelvic and lower-extremity fractures.
Topics: Adult; Aged; Anticoagulants; Bones of Lower Extremity; Chemoprevention; Dabigatran; Enoxaparin; Female; Fractures, Bone; Humans; Male; Middle Aged; Multidetector Computed Tomography; Pelvic Bones; Pulmonary Embolism; Risk Factors; Sex Factors; Venous Thromboembolism; Venous Thrombosis; Young Adult | 2020 |
Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Antithrombins; Chest Pain; Computed Tomography Angiography; Dabigatran; Decision Making, Shared; Dyspnea; Enoxaparin; Hospitalization; Humans; Male; Middle Aged; Myelitis, Transverse; Patient Transfer; Physicians, Primary Care; Pulmonary Embolism; Risk Assessment; Treatment Outcome; Venous Thrombosis | 2020 |
Thromboembolic and bleeding complications following primary total knee arthroplasty : a Danish nationwide cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antithrombins; Arthroplasty, Replacement, Knee; Dabigatran; Dalteparin; Denmark; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Male; Middle Aged; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Proportional Hazards Models; Registries; Rivaroxaban; Tinzaparin; Venous Thromboembolism; Young Adult | 2021 |